287 related articles for article (PubMed ID: 32919178)
21. Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous Thromboembolism.
Hussaini P; Larsen TL; Ghanima W; Dahm AEA
Thromb Haemost; 2024 Apr; 124(4):351-362. PubMed ID: 37816388
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Direct-Acting Oral Anticoagulant Use in Patients With Cancer.
Davis DO; Davis KA
J Pharm Pract; 2018 Oct; 31(5):441-444. PubMed ID: 28803521
[TBL] [Abstract][Full Text] [Related]
23. Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial.
Imamura Y; Otsui K; Mori K; Kitagawa K; Okada H; Hata A; Hayashi H; Nose T; Ohata S; Miyata Y; Funakoshi Y; Toyoda M; Yakushijin K; Kiyota N; Matsuoka H; Minami H
Int J Hematol; 2022 Apr; 115(4):499-507. PubMed ID: 35079961
[TBL] [Abstract][Full Text] [Related]
24. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial.
Becattini C; Bauersachs R; Maraziti G; Bertoletti L; Cohen A; Connors JM; Manfellotto D; Sanchez A; Brenner B; Agnelli G
Haematologica; 2022 Jul; 107(7):1567-1576. PubMed ID: 34382385
[TBL] [Abstract][Full Text] [Related]
25. Safety and Effectiveness of Direct Oral Anticoagulants for the Treatment of Gastrointestinal Cancer-Associated Venous Thromboembolism.
Ullah F; Song J; Rojas Hernandez CM; Kroll MH; Escalante CP; Toale KM
Oncologist; 2023 Nov; 28(11):e1005-e1016. PubMed ID: 37310796
[TBL] [Abstract][Full Text] [Related]
26. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity.
Crouch A; Ng TH; Kelley D; Knight T; Edwin S; ; Giuliano C
Pharmacotherapy; 2022 Feb; 42(2):119-133. PubMed ID: 34904263
[TBL] [Abstract][Full Text] [Related]
27. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
[TBL] [Abstract][Full Text] [Related]
28. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
[No Abstract] [Full Text] [Related]
29. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of direct oral anticoagulants for the treatment of venous thromboembolism in the oncology population.
Hedvat J; Howlett C; McCloskey J; Patel R
J Thromb Thrombolysis; 2018 Nov; 46(4):483-487. PubMed ID: 30191357
[TBL] [Abstract][Full Text] [Related]
31. Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism.
Bott-Kitslaar DM; McBane RD; Casanegra AI; Houghton DE; Froehling DA; Vlazny DT; Ashrani AA; Hodge DO; Vargas ER; Bartlett MA; Saadiq RA; Daniels PR; Shields RC; Lenz CJ; Lang TR; Wysokinski WE
Mayo Clin Proc; 2019 Jul; 94(7):1242-1252. PubMed ID: 30737059
[TBL] [Abstract][Full Text] [Related]
32. Oral apixaban for the treatment of acute venous thromboembolism.
Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE; Weitz JI;
N Engl J Med; 2013 Aug; 369(9):799-808. PubMed ID: 23808982
[TBL] [Abstract][Full Text] [Related]
33. Comparison of effectiveness and safety for low versus full dose of apixaban during extended phase oral anticoagulation in patients with venous thromboembolism.
DeRemer CE; Dietrich EA; Kang HR; Huang PL; Lo-Ciganic WH; Park H
J Intern Med; 2022 Jun; 291(6):877-885. PubMed ID: 35192737
[TBL] [Abstract][Full Text] [Related]
34. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
McBane RD; Wysokinski WE; Le-Rademacher JG; Zemla T; Ashrani A; Tafur A; Perepu U; Anderson D; Gundabolu K; Kuzma C; Perez Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Houghton DE; Vishnu P; Loprinzi CL
J Thromb Haemost; 2020 Feb; 18(2):411-421. PubMed ID: 31630479
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.
Dawwas GK; Brown J; Dietrich E; Park H
Lancet Haematol; 2019 Jan; 6(1):e20-e28. PubMed ID: 30558988
[TBL] [Abstract][Full Text] [Related]
36. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
van Es N; Coppens M; Schulman S; Middeldorp S; Büller HR
Blood; 2014 Sep; 124(12):1968-75. PubMed ID: 24963045
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain.
Muñoz A; Gallardo E; Agnelli G; Crespo C; Forghani M; Arumi D; Fernández de Cabo S; Soto J
J Med Econ; 2022; 25(1):840-847. PubMed ID: 35703036
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
Arce-Huamani MA; Barboza JJ; Martínez-Herrera JF; Torres-Roman JS; Maguiña JL
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893585
[No Abstract] [Full Text] [Related]
39. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Bird A; Mitchell SA; Li S; Horblyuk R; Batson S
PLoS One; 2016; 11(8):e0160064. PubMed ID: 27487187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
